文献速递胸部肿瘤放疗乳腺癌放疗泌尿生殖与妇科肿瘤放疗

寡进展性疾病的局部治疗:前瞻性试验的系统综述

Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-08-13

本PRISMA系统综述纳入8项前瞻性试验共290例患者,进展均发生于正在进行的全身治疗且进展部位≤5个并全部接受局部治疗。局部治疗耐受良好,仅7例3级及以上毒性;非小细胞肺癌随机试验显示局部治疗改善无进展生存,但乳腺癌未获益。作者认为基于有限数据局部治疗安全且短期初步结果令人鼓舞,但需更大样本和更长随访的试验。

要点

  • 8项前瞻性试验共290例患者,绝大多数以立体定向放疗为局部治疗方式。
  • 唯一随机试验显示局部治疗改善非小细胞肺癌无进展生存,但乳腺癌未获益。
  • 全部试验合计仅7例3级及以上毒性,局部治疗耐受良好。

核心结论

  • 基于有限数据,寡进展的局部治疗是安全的,并产生令人鼓舞的短期初步结果,但需要更大样本量和更长随访的试验才能得出更稳健的结论。

研究设计与样本

  • PRISMA指导的系统综述,仅纳入前瞻性数据,要求进展发生于正在进行的全身治疗、进展部位明确列出且≤5个、所有进展部位均接受局部治疗(放疗/手术/非放疗消融),共纳入8项试验290例患者。

主要发现

  • 关于非小细胞肺癌的研究显示,与单纯全身治疗的历史值相比,立体定向放疗改善了无进展生存和总生存。
  • 另外两项关于表皮生长因子受体突变非小细胞肺癌的研究显示,局部治疗的无进展生存可接受,尤其是在奥希替尼治疗期间寡进展的患者中。
  • 本分析中唯一的随机试验显示,局部治疗改善了非小细胞肺癌的无进展生存,但未改善乳腺癌的无进展生存。
  • 两项去势抵抗性前列腺癌试验显示,相当比例的患者不需要改变激素治疗或延迟了改变全身治疗的需要。
  • 两项肾细胞癌试验显示局部控制率高(90%-100%),中位无进展生存为9个月,并可能延长改变全身治疗的时间。

关键数值与推荐

  • 立体定向放疗最常用的剂量方案为19-20 Gy分1次、27-33 Gy分3次或35-50 Gy分5次。
  • 所有试验全部患者中,仅7例出现3级及以上毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 基于有限数据,需要更大样本量和更长随访的试验才能得出更稳健的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The successes of local therapy for oligometastatic cancers cannot be extrapolated to oligoprogressive disease (OPD) because they are distinct clinical entities. Given the limited prospective data on OPD to date, summative analyses are urgently needed. METHODS AND MATERIALS: Inclusion criteria for this Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided systematic review were as follows. First, only prospective data were included. Second, progression had to have occurred on active/ongoing systemic therapy. Third, the number of progressing areas of disease had to be explicitly listed and ≤5 in number. Fourth, all progressing sites had to undergo local therapy (radiation therapy [RT] /surgery/nonradiation ablative procedures). RESULTS: Eight trials met criteria (summing 290 patients), the vast majority of which used stereotactic RT as the local modality (most commonly, 19-20 Gy in 1 fraction, 27-33 Gy in 3 fractions, or 35-50 Gy in 5 fractions). A study on non-small cell lung cancer (NSCLC) demonstrated that stereotactic RT improved progression-free survival (PFS) and overall survival compared with historical values with systemic therapy alone. Two additional studies on epidermal growth factor receptor mutated (EGFRm) NSCLC also showed acceptable PFS with local therapy, particularly in patients who oligoprogressed on osimertinib. The only randomized trial analyzed herein showed that local therapy improved PFS for NSCLC but not breast cancer. Two trials in castration-resistant prostate cancer illustrated that a substantial proportion of patients did not require any changes in hormonal therapy or delayed the need to change systemic therapies. Lastly, 2 trials of renal cell carcinoma showed high (90%-100%) local control and median PFS of 9 months, and potentially a prolonged time to change systemic therapy. Lastly, from all patients in all trials, local therapy was tolerated well, with only 7 instances of grade 3+ toxicities. CONCLUSIONS: Based on the limited data, local therapy for oligoprogression is safe and yields encouraging short-term preliminary outcomes, but trials with larger sample sizes and longer follow-up are required for more robust conclusions.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim H, Venkatesulu BP, McMillan MT, et al. Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials. Int J Radiat Oncol Biol Phys. 2022. PMID: 35973624. doi:10.1016/j.ijrobp.2022.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。